Shots:

• Arbor to receive an up front in cash & is eligible to receive an additional ~$1.2B on achievement of milestones across up to 7 programs along with royalties on sales on products emerges from the collaboration. Vertex will also invest in Arbor in the form of a convertible note
• Vertex get rights to use Arbor's technology to research & develop ex vivo engineered cell therapies for T1D- beta thalassaemia- sickle-cell disease- and other diseases
• The collaboration follows the 2018 agreement & will expands Vertex’s cell and gene therapies targeting multiple serious diseases. The agreement also determines the versatility and strength of Arbor’s platform

Click here  | Ref: Globe Newswire | Image: Vertex